Pemetrexed

Pemetrexed is indicated for:

  • Initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) in combination with cisplatin.
  • Maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as a single agent.
  • Treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy, as a single agent.

There are no products to list in this category.